Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Caris Life Sciences Inc. (CAI)

NASDAQ: CAI · Services-Medical Laboratories · Irving, TX

Our rating: Positive

Positive reaffirmed at $18.54, moderate conviction, November 19, 2026.

Breaks if: The Positive view breaks if reported revenue growth in the next full fiscal year prints below 20% year-over-year — which would indicate the near-doubling was a one-time reimbursement or adoption event rather than a durable inflection — or if free cash flow turns negative in any two consecutive reported quarters. A drawdown of 30% or more from $18.54 within the next 252 trading days would signal the market has fundamentally reassessed the growth story.

Key figures

Market value$5.0B
Revenue, last 12 months$1.0B
Net income, last 12 months$96M
Free cash flow, last 12 monthsn/a
Price to earnings52.5×
Free cash flow yieldn/a
Dividend yield0.0%
Operating margin13.4%
Return on equity17.2%
Beta to the S&P 5001.72
Volatility, annualized68.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$275M27.0%$0.05−$40M
June 30, 2026$264M45.4%$0.00n/a
March 31, 2026$216M78.8%$0.00$23M
December 31, 2025$293M125.4%$1.61$40M
September 30, 2025$217M113.4%$0.08$55M
June 30, 2025$181M81.3%$-7.97$6M
March 31, 2025$121Mn/a$-3.57−$34M
December 31, 2024$130Mn/a$-1.74−$41M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

34 ledger entries and 2 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.